

## Medivir to merge Research and Development and implement changes within the management group

**Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR)** today announces that, as the next step in the company's optimisation process, its research and development operations will be merged into a joint unit as of 1 October 2015, headed by Richard Bethell who will hold the new title of EVP Research & Development. The new unit will span the entire process, from the early research to the late-stage development phases.

This change will both increase Medivir's ability to prioritise and enhance efficiency within its research operations and expand the flexibility and readiness for a broadening of the development portfolio. Regarded as a whole, these measures will further strengthen Medivir's ability to generate long-term value through research and development, based on the company's established, documented and successful technology platform.

Medivir will also create a new function to house all regulatory skills and areas of responsibility, headed by Åsa Holmgren who will hold the new title of EVP Strategic Regulatory Affairs. Åsa, who was recently recruited to the company, hereby becomes a member of Medivir's management group.

In light of the reorganization process, Charlotte Edenius, EVP Development, has chosen to take on new challenges outside Medivir.

"Charlotte has most admirably built up a development organization with a wide area of expertise, which enables Medivir to efficiently run projects from the selection of a candidate drug to clinical studies on patients. I would like to take this opportunity to thank Charlotte Edenius for her huge commitment and valuable performance, and at the same time welcome Åsa Holmgren to the management group," says Niklas Prager, President and CEO of Medivir AB.

### **For further information, please contact:**

Niklas Prager, President & CEO, mobile: +46 (0) 76 811 7744.

### **About Medivir**

Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.